H Lundbeck A/S (HLUYY) 41.4800 $HLUYY
Don't Make it Complicated, Own Drug Stocks
John Blank - Zacks Investment Research - Thu Jun 16, 6:46PM CDT
The Large Cap Pharma Industry usually looks like a solid investor niche. Place a few of your stock picking bets here.
PFE: 34.79 (-0.32), BMY: 59.41 (-0.62)
Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:30AM CDT
Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
PFE: 34.79 (-0.32), BMY: 59.41 (-0.62)
Why H. Lundbeck (HLUYY) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:46AM CDT
H. Lundbeck (HLUYY) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
3 Reasons Momentum Stock Investors Will Love H. Lundbeck (HLUYY)
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:33AM CDT
H. Lundbeck is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
Large Pharmaceutical Stocks Should Be On Your Buying Radar
Maher Syed - Zacks Investment Research - Mon Apr 04, 3:27PM CDT
This industry has moved up over 100 ranks in the last week! don't miss out on the great stocks in this space.
NVO: 47.12 (+0.52), LLY: 79.84 (-0.42)
Biotie Therapies Soars on $363M Buyout Deal with Acorda
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 3:25PM CST
Acorda Therapeutics (ACOR) entered into an agreement to acquire Finnish biotech company Biotie Therapies for $363 million; the deal is expected to position Acorda as a leader in Parkinson's disease development.
BITI: 25.80 (-0.71), ACOR: 24.05 (-0.21), ANIK: 49.33 (-0.27)
Chinese Stock Market Rodeo Reopens: Global Week Ahead
John Blank - Zacks Investment Research - Mon Nov 09, 9:39AM CST
Heedless of fundamentals, Chinese retail investors and traders love to chase momentum. Upside is back in vogue.
NVO: 47.12 (+0.52), CBRL: 160.00 (-0.08), CAH: 82.68 (-0.51)
3 Reasons Why H. Lundbeck A/S (HLUYY) is a Great Momentum Stock
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 7:30AM CDT
H. Lundbeck A/S has a strong momentum score, a favorable Zacks Rank, and is seeing positive earnings estimate revisions as well
How H. Lundbeck A/S (HLUYY) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 7:56AM CDT
H. Lundbeck A/S in the Large Cap Pharma space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
Is H. Lundbeck A/S (HLUYY) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 07, 7:36AM CDT
If you are looking for a decent pick in a strong industry, consider H. Lundbeck A/S
Lundbeck Initiates Clinical Trial Evaluating Clobazam for Dravet Syndrome
BusinessWire - Tue Mar 17, 9:00AM CDT
Lundbeck LLC today announced the initiation of the CLOVER I Study to investigate the use of clobazam for the treatment of children and adolescents with Dravet syndrome -- a rare and severe form of intractable epilepsy that begins in infancy.(1) Clobazam is already approved in the United States (U.S.) for seizures associated with another epilepsy syndrome.
New Study: Art Therapy May Build Self-Esteem in People Living with Epilepsy
BusinessWire - Mon Dec 08, 10:00AM CST
--Studio E Artwork on Display Across the Country to Raise Epilepsy Awareness
Don't Make it Complicated, Own Drug Stocks
John Blank - Zacks Investment Research - Thu Jun 16, 6:46PM CDT
The Large Cap Pharma Industry usually looks like a solid investor niche. Place a few of your stock picking bets here.
PFE: 34.79 (-0.32), BMY: 59.41 (-0.62)
Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:30AM CDT
Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
PFE: 34.79 (-0.32), BMY: 59.41 (-0.62)
Why H. Lundbeck (HLUYY) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:46AM CDT
H. Lundbeck (HLUYY) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
3 Reasons Momentum Stock Investors Will Love H. Lundbeck (HLUYY)
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:33AM CDT
H. Lundbeck is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
Large Pharmaceutical Stocks Should Be On Your Buying Radar
Maher Syed - Zacks Investment Research - Mon Apr 04, 3:27PM CDT
This industry has moved up over 100 ranks in the last week! don't miss out on the great stocks in this space.
NVO: 47.12 (+0.52), LLY: 79.84 (-0.42)
Biotie Therapies Soars on $363M Buyout Deal with Acorda
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 3:25PM CST
Acorda Therapeutics (ACOR) entered into an agreement to acquire Finnish biotech company Biotie Therapies for $363 million; the deal is expected to position Acorda as a leader in Parkinson's disease development.
BITI: 25.80 (-0.71), ACOR: 24.05 (-0.21), ANIK: 49.33 (-0.27)
Chinese Stock Market Rodeo Reopens: Global Week Ahead
John Blank - Zacks Investment Research - Mon Nov 09, 9:39AM CST
Heedless of fundamentals, Chinese retail investors and traders love to chase momentum. Upside is back in vogue.
NVO: 47.12 (+0.52), CBRL: 160.00 (-0.08), CAH: 82.68 (-0.51)
3 Reasons Why H. Lundbeck A/S (HLUYY) is a Great Momentum Stock
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 7:30AM CDT
H. Lundbeck A/S has a strong momentum score, a favorable Zacks Rank, and is seeing positive earnings estimate revisions as well
How H. Lundbeck A/S (HLUYY) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 7:56AM CDT
H. Lundbeck A/S in the Large Cap Pharma space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
Is H. Lundbeck A/S (HLUYY) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 07, 7:36AM CDT
If you are looking for a decent pick in a strong industry, consider H. Lundbeck A/S
Lundbeck Initiates Clinical Trial Evaluating Clobazam for Dravet Syndrome
BusinessWire - Tue Mar 17, 9:00AM CDT
Lundbeck LLC today announced the initiation of the CLOVER I Study to investigate the use of clobazam for the treatment of children and adolescents with Dravet syndrome -- a rare and severe form of intractable epilepsy that begins in infancy.(1) Clobazam is already approved in the United States (U.S.) for seizures associated with another epilepsy syndrome.
New Study: Art Therapy May Build Self-Esteem in People Living with Epilepsy
BusinessWire - Mon Dec 08, 10:00AM CST
--Studio E Artwork on Display Across the Country to Raise Epilepsy Awareness
